Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Regencell Bioscience Holdings Limited (RGC : NSDQ)
 
 • Company Description   
Regencell Bioscience Holdings Limited is an early-stage bioscience company which focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. Regencell Bioscience Holdings Limited is based in HONG KONG.

Number of Employees: 13

 
 • Price / Volume Information   
Yesterday's Closing Price: $24.50 Daily Weekly Monthly
20 Day Moving Average: 18,492 shares
Shares Outstanding: 12.64 (millions)
Market Capitalization: $309.73 (millions)
Beta:
52 Week High: $59.00
52 Week Low: $6.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 11.36% 21.57%
12 Week -35.53% -30.32%
Year To Date -23.08% -8.89%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11/F FIRST COMMERCIAL BUILDING 33-35 LEIGHTON ROAD CAUSEWAY BAY
-
HONG KONG,K3 999077
HKG
ph: 852-2155-0823
fax: 852-2155-0853
None http://www.regencellbioscience.com
 
 • General Corporate Information   
Officers
Yat-Gai Au - Chairman; Director and Chief Executive Officer
James Wai Hong Chung - Chief Operation Officer and Chief Strategy Officer
Tien Hsiang Chau - Chief Financial Officer
Evana Yee Wah Hui - Director
Paul J. Niewiadomski - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G7487R100
SIC: 2833
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 12.64
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $309.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©